research Emerging drugs for alopecia areata: JAK inhibitors
JAK inhibitors may soon be a safe and effective treatment for alopecia areata.
Search
for
Sort by
Research
30-60 / 1000+ results 
research Real-World Evidence for Baricitinib in the Treatment of Atopic Dermatitis and Alopecia Areata: Systematic Literature Review 2020–2023
Baricitinib effectively improves symptoms of atopic dermatitis and alopecia areata with few side effects.
research Physician- and Patient-Reported Severity and Quality of Life Impact of Alopecia Areata: Results from a Real-World Survey in Five European Countries
Alopecia areata severely impacts quality of life, causing anxiety, depression, and work impairment.
research Methods of Using of Cosmeceuticals in Trichological Practice
Use personalized cosmeceuticals for safe, effective hair and scalp treatment.
research Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review
Some treatments for severe hair loss work but often have side effects, with baricitinib showing the most promise.
research Alopecia Areata: The Clinician and Patient Voice
Alopecia areata causes unpredictable hair loss and emotional distress, with no cure and limited treatment options.
research Real-World Treatment Patterns among Patients with Alopecia Areata in the USA: A Retrospective Claims Analysis
Corticosteroids are the most common treatment for alopecia areata, but many patients need better options.
research Janus Kinase inhibitors in dermatology: a review
JAK inhibitors effectively treat skin conditions and topical forms are safer.
research A Cost-per-Responder Analysis of Ritlecitinib vs Baricitinib in Severe Alopecia Areata
Ritlecitinib is more effective and cheaper than baricitinib for treating severe alopecia areata.
research Patient Profile and Treatment Characteristics of Adults and Adolescents Prescribed Ritlecitinib for Alopecia Areata in the USA
Ritlecitinib provides new treatment options for diverse alopecia areata patients.
research Novel drugs of United States Food and Drug Administration approved in 2024
In 2024, the FDA approved 50 new drugs, including treatments for hair loss, anemia, high blood pressure, and Alzheimer's.
research Treatment Patterns and Health-Related Quality of Life in Patients with Alopecia Areata Stratified by Disease Severity in the USA
More severe alopecia areata can lower quality of life.
research Medicaid coverage of Janus kinase inhibitors for alopecia areata treatment
Medicaid coverage for alopecia areata treatments is inconsistent and often limited.
research Evidence Synthesis Gone Awry: The Perils of Aggregating Ineffective or Unsafe Doses in Alopecia Areata Reviews
Including ineffective or unsafe doses in reviews can lead to misleading conclusions about alopecia areata treatments.
research Hair for the Long Haul: Alopecia Areata Cases and Considerations
JAK inhibitors are effective for long-term management of alopecia areata.
research Baricitinib Provides Holistic Improvement in Scalp, Eyebrow and Eyelash Regrowth in Adolescents With Severe Alopecia Areata
Baricitinib helps regrow scalp, eyebrow, and eyelash hair in teens with severe alopecia areata.
research The Burden of Alopecia Areata and Management with Baricitinib in the United Arab Emirates: A Narrative Review
Baricitinib is a promising treatment for alopecia areata in the UAE, but there are challenges with data and access.
research Exploring Factors That Influence the Measurement of Patient-Reported Impacts of Alopecia Areata
Significant, lasting hair regrowth is needed to improve how patients with Alopecia Areata feel about their condition.
research Patient Validation of Estimation of Health Utility Values in Alopecia Areata
Patients with Alopecia Areata are willing to trade life duration for better quality of life.
research Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique
De nouvelles thérapies promettent de mieux traiter la perte de cheveux due à l'alopécie androgénétique.
research Baricitinib Withdrawal and Retreatment in Patients With Severe Alopecia Areata
Continuous baricitinib is needed to keep hair regrowth in severe alopecia areata.
research Alopecia areata, actualización clínica y terapéutica
Understanding and treating alopecia areata improves patient care.
research Characteristics and Management of Patients with Alopecia Areata and Selected Comorbid Conditions: Results from a Survey in Five European Countries
AA patients with comorbid conditions face more severe hair loss and need specific treatments.
research Patient-Reported Burden of Severe Alopecia Areata: First Results from the Multinational Alopecia Areata Unmet Need Survey
Severe alopecia areata greatly impacts quality of life, mental health, and daily activities.
research Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
research Treatment Patterns and Unmet Needs in the Management of Alopecia Areata: Results of a Physician’s Survey in the Middle East
Doctors in the Middle East need better treatments and more knowledge about new therapies for hair loss condition Alopecia Areata.
research Lipid nanocarriers as innovative strategies for hair regrowth
Lipid nanocarriers could effectively promote hair regrowth with fewer side effects.
research Farmácia Padrão da Légua, Custóias e nos Serviços Farmacêuticos da Klinicka Bolnica Dubrava, Croácia
Pharmacists play a crucial role in safe medication use and interdisciplinary collaboration is key to reducing antimicrobial resistance.
research Janus Kinase Inhibitors for Alopecia Areata
JAK inhibitors effectively improve hair regrowth in alopecia areata with an acceptable safety profile.
research Journal of Population Therapeutics and Clinical Pharmacology
Baricitinib is more effective than methotrexate for severe alopecia areata.